The role of targeted therapy in the treatment of advanced colorectal cancer

Current Treatment Options in Oncology

Volumn 9, Issue 4-6, 2008, Pages 357-374

  Fakih, Marwan ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PLACEBO; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLFOX PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ARTERY THROMBOSIS; BLOOD VESSEL INJURY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG COMPETITION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; LIVER INJURY; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; NEUTROPENIA; PERFORATION; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70249088743     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-009-0089-1     Document Type: Review

References (74)

1. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905-14. doi: 10.1056/NEJM200009283431302.
2. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355(9209):1041-7. doi: 10.1016/S0140-6736(00)02034-1.
3. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL.: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345(2): 144-145; author reply 6. doi: 10.1056/ NEJM200107123450213.
4. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-47.
5. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30. doi: 10.1200/JCO.2004.09.046.
6. Colucci G, Gebbia V, Paoletti G, et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 23(22):4866-75. doi: 10.1200/JCO.2005.07.113.
7. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004, 22(2):229-37. doi: 10.1200/JCO.2004.05.113.
8. Cassidy J, Clarke S, Diaz-Rubio E, et al.: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.
9. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al.: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007, 25(27):4224-30. doi: 10.1200/JCO.2006.09.8467.
10. Ducreux M, Bennouna J, Hebbar M, et al.: Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007, 25, abstract 4029
11. Porschen R, Arkenau HT, Kubicka S, et al.: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 2007, 25(27):4217-23. doi: 10.1200/JCO.2006.09.2684.
12. Fuchs CS, Marshall J, Mitchell E, et al.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-86. doi: 10.1200/ JCO.2007.11.3357.
13. Koopman M, Antonini NF, Douma J, et al.: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007, 370(9582):135-42. doi: 10.1016/S0140-6736(07)61086-1.
14. Seymour MT, Maughan TS, Ledermann JA, et al.: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007, 370(9582):143-52. doi: 10.1016/S0140-6736(07)61087-3.
15. Seymour MT, Punt CJ: CAIRO and FOCUS. Lancet 2007, 370(9603): 1904-1905; author reply 5. doi: 10.1016/S0140-6736(07)61807-8
16. TourAigand C, Cervantes A, Figer A, et al.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006, 24(3):394-400. doi: 10.1200/JCO.2005.03.0106.
17. Maindrault-Goebel F, Lledo G, Chibaudel B, et al.: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 2007, 25, abstract 4013
18. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23(36):9441-2. doi: 10.1200/JCO.2005.04.4792.
19. Hicklin DJ, Ellis LM.: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-27. doi: 10.1200/JCO.2005.06.081.
20. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1):60-5. doi: 10.1200/JCO.2003.10.066.
21. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-42. doi: 10.1056/NEJMoa032691.
22. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S.: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23(16):3706-12. doi: 10.1200/ JCO.2005.00.232.
23. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007, 99(16):1232-9. doi: 10.1093/jnci/djm086.
24. Fuchs CS, Marshall J, Barrueco J.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008, 26(4):689-90. doi: 10.1200/ JCO.2007.15.5390.
25. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008, 26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.
26. Giantonio B, Meropol N, Catalano P, et al.: Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies. J Clin Oncol 2007, 25, abstract 4073
27. Hochster HS, Hart LL, Ramanathan RK, et al.: Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. J Clin Oncol 2008, 26(21):3523-9. doi: 10.1200/ JCO.2007.15.4138.
28. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-44. doi: 10.1200/JCO.2006.09.6305.
29. Kozloff M, Hainsworth J, Badarinath S, et al.: Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006, 24(18S): 3537
30. Kretzschmar A, Van Cutsem E, Michael M, et al.: Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial. J Clin Oncol 2007, 25, abstract 4072
31. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-64. doi: 10.1200/JCO.2006.08.1620.
32. Hecht J, Chidiac T, Mitchell E, et al.: An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC): Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann Oncol 2007, 18, vii21
33. Hecht JR, Mitchell E, Chidiac T, et al.: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(5): 672-680
34. Siena S, Tabernero J, Burkes R, et al.: Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. J Clin Oncol 2008, 26, abstract 4034
35. Peeters M, Wilson G, Ducreux M, et al.: Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. J Clin Oncol 2008, 26, abstract 4064
36. Van Cutsem E, Nowacki M, Lang I, et al.: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007, 25(18S):4000
37. Bokemeyer C, Bondarenko I, Makhson A, et al.: Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007, 25, abstract 4035
38. Bokemeyer C, Bondarenko I, Hartmann J, et al.: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008, 26, abstract 4000
39. Punt C, Tol J, Rodenburg C, et al.: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008, 26, abstract LBA4011
40. Brink M, de Goeij AF, Weijenberg MP, et al.: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003, 24(4):703-10. doi: 10.1093/carcin/bgg009.
41. Bazan V, Migliavacca M, Zanna I, et al.: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002, 13(9):1438-46. doi: 10.1093/annonc/mdf226.
42. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001, 85(5):692-6. doi: 10.1054/bjoc.2001.1964.
43. Van Cutsem E, Lang I, D'haens G, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008, 26, abstract 2
44. Grothey A, Sugrue M, Hedrick E, et al.: Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). J Clin Oncol 2007, 25, abstract 4036
45. Pobrero AF, Maurel J, Fehrenbacher L, et al.: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-9. doi: 10.1200/JCO.2007.13.1193.
46. Fakih MG, Wilding G, Lombardo J.: Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clinical colorectal cancer 2006, 6(2):152-6. doi: 10.3816/CCC.2006.n.033.
47. Tejpar S, Piessevaux H, Claes K, et al.: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. The lancet oncology 2007, 8(5):387-94. doi: 10.1016/S1470-2045(07)70108-0.
48. Fakih M.: Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology Williston Park NY 2008, 22(1):74-6.
49. Adam R, Aloia T, Levi F, et al.: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25(29):4593-602. doi: 10.1200/JCO.2007.10.8126.
50. Di Fiore F, Van Cutsem E, Laurent-Puig P, et al.: Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. J Clin Oncol 2008, 26, abstract 4035
51. Rothenberg M, Oza A, Burger B, et al.: Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. J Clin Oncol 2003, 22, abstract 1011
52. Chen HX, Mooney M, Boron M, et al.: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006, 24(21):3354-60. doi: 10.1200/ JCO.2005.05.1573.
53. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-45. doi: 10.1056/NEJMoa033025.
54. Lievre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191.
55. Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-9. doi: 10.1200/ JCO.2007.12.5906.
56. Di Fiore F, Blanchard F, Charbonnier F, et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96(8):1166-9. doi: 10.1038/sj.bjc.6603685.
57. De Roock W, Piessevaux H, De Schutter J, et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19(3):508-15. doi: 10.1093/annonc/mdm496.
58. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-8. doi: 10.1056/NEJMoa071834.
59. Khambata-Ford S, Garrett CR, Meropol NJ, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-7. doi: 10.1200/JCO.2006.10.5437.
60. Amado RG, Wolf M, Peeters M, et al.: Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2008, 26(10): 1626-1634
61. Saltz LB, Lenz HJ, Kindler HL, et al.: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007, 25(29):4557-61. doi: 10.1200/JCO.2007.12.0949.
62. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA.: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006, 141(6):537-43; discussion 43-4. doi: 10.1001/archsurg.141.6.537.
63. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of surgery 2004, 239(6):818-25; discussion 25-7. doi: 10.1097/ 01.sla.0000128305.90650.71.
64. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM.: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of surgery 2004, 240(3):438-47; discussion 47-50. doi: 10.1097/01.sla.0000138076.72547.b1.
65. Sanoff HK, Sargent DJ, Campbell ME, et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008, 26(35): 5721-5727
66. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Annals of surgery 2004, 240(4):644-57; discussion 57-58.
67. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH.: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005, 16(8):1311-9. doi: 10.1093/annonc/mdi246.
68. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25(13):1670-6. doi: 10.1200/JCO.2006.09.0928.
69. Leonard GD, Brenner B, Kemeny NE.: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005, 23(9):2038-48. doi: 10.1200/ JCO.2005.00.349.
70. Gruenberger B, Tamandl D, Schueller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26(11):1830-5. doi: 10.1200/JCO.2007.13.7679.
71. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008, 5(10): 2765-2772
72. Reddy SK, Morse MA, Hurwitz HI, et al.: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. Journal of the American College of Surgeons 2008, 206(1):96-106. doi: 10.1016/j.jamcollsurg.2007.06.290.
73. Ribero D, Wang H, Donadon M, et al.: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110(12):2761-7. doi: 10.1002/cncr.23099.
74. Klinger M, Kandutsch S, Hacker S, Gruenberger B, Gruenberger T: Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: effect of bevacizumab. J Clin Oncol 2008, 26, abstract 4082